Susan Catalano, PhD, of Cognition Therapeutics Inc., Pittsburgh, PA, discusses therapeutics designed to mimic protective mutations. Dr Catalano mentions that for other indications these therapeutic agents have been clinically successful. For Alzheimer’s disease, drugs that replicate the protective effects of the A673T mutation, such as CT1812, and significantly reduce oligomer binding to synapses in the brain may be effective treatments. This interview was recorded during an online conference call with The Video Journal of Dementia (VJDementia).
